Medivation Inc  

(Public, NASDAQ:MDVN)   Watch this stock  
Find more results for MDVN
101.87
+2.47 (2.48%)
Oct 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 99.28 - 102.16
52 week 54.37 - 103.88
Open 99.39
Vol / Avg. 758,479.00/1.25M
Mkt cap 7.63B
P/E 369.32
Div/yield     -
EPS 0.28
Shares 76.79M
Beta 0.78
Inst. own 97%
Nov 6, 2014
Q3 2014 Medivation Inc Earnings Call - 4:30PM EST - Add to calendar
Nov 6, 2014
Q3 2014 Medivation Inc Earnings Release - 4:00PM EST - Add to calendar
Sep 11, 2014
Medivation Inc and Astellas Pharma Inc Announce FDA Approval of New Indication for the Use of XTANDI (enzalutamide) Capsules
Sep 3, 2014
Medivation Inc at Citi Biotech Conference
Aug 7, 2014
Q2 2014 Medivation Inc Earnings Call
Aug 7, 2014
Q2 2014 Medivation, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 32.36% -15.61%
Operating margin 37.11% -8.15%
EBITD margin - -6.88%
Return on average assets 43.62% -11.15%
Return on average equity 170.63% -56.59%
Employees 370 -
CDP Score - -

Address

36th Floor, 525 Market Street
SAN FRANCISCO, CA 94105
United States - Map
+1-415-5433470 (Phone)
+1-415-5433411 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Medivation, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapies. The Company advanced program XTANDI (enzalutamide) capsules, or XTANDI, is partnered with Astellas Pharma Inc. ( Astellas). Together with Astellas, the Company is also conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC patients, and in patients with breast cancer. It also has ongoing programs with other agents in multiple different indications in early stages of research and development. The Company and Astellas also conduct the TERRAIN trial and the STRIVE trial, two randomized, double-blind Phase 2 trials evaluating enzalutamide head-to-head versus bicalutamide, the marketed anti-androgen drug, in pre-chemotherapy castration-resistant prostate cancer (CRPC patients).

Officers and directors

Kim D. Blickenstaff Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
David T. Hung M.D. President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Rick Bierly Chief Financial Officer, Principal Financial and Accounting Officer
Age: 58
Bio & Compensation  - Reuters
Stephen M. Kelsey M.D. Senior Vice President - New Projects
Age: 53
Bio & Compensation  - Reuters
Jennifer J. Rhodes Chief Compliance Officer, General Counsel, Corporate Secretary
Age: 44
Bio & Compensation  - Reuters
Dawn Svoronos Interim Chief Commercial Officer, Director
Age: 60
Bio & Compensation  - Reuters
Lynn Seely M.D. Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
C. Patrick Machado J.D. Director
Age: 50
Bio & Compensation  - Reuters
Kathryn E. Falberg Independent Director
Age: 53
Bio & Compensation  - Reuters
W. Anthony Vernon Independent Director
Age: 58
Bio & Compensation  - Reuters